EGFR、HER2、c-jun、c-fos、P^(21)、P^(16)、P^(53)在非小细胞肺癌中的表达及临床病理特征

Expression and Pathological Characteristics of EGFR、HER2、c-jun、c-fos、p21、p16、p53 in NSCLC

目的探讨EGFR、HER2、c-jun、c-fos、P21、P16、P53在非小细胞肺癌(NSCLC)中的表达及临床病理特征。方法采用荧光原位杂交技术(FISH)和免疫组织化学法(SP)检测64例非小细胞肺癌组织中EGFR、HER2、c-jun、c-fos、P21、P16、P53的表达。结果 (1)64例NSCLC中,EGFR和HER2阳性扩增率分别为39.0%和29.7%,在不同病理分级、不同临床TNM分期及有无淋巴结转移间无显著差异(P>0.05)。HER2基因在腺癌的扩增率明显高于鳞癌(P<0.05)。(2)c-jun、c-fos、P21、P16、P53蛋白在不同临床TNM分期有明显差异(P<0.05),在不同病理类型及分级间无明显差异(P>0.05),P53的表达水平在淋巴结转移组明显高于无淋巴结转移组(P<0.05)。(3)EGFR与HER2、c-jun、c-fos、P21的表达水平在NSCLC中呈正相关。结论联合检测EGFR、HER2、c-jun、c-fos、P21、P16、P53,有助于为NSCLC的早期诊断及个体化治疗提供新思路和新方法。NSCLC中,HER2、c-jun、c-fos、P21在EGFR介导的信号传导通路中发挥了正性调节的作用。

Objective To discuss the expression and pathological characteristics of EGFR,HER2 ,c- jun,c- fos, p21 ,p16 ,p53 in NSCLC. Methods 64 cases of such patient were detected in expression of EGFR,HER2,c -jun, c - fos,p21 p16 ,p53 with FISH and SP. Results The positive amplification were 39.0% and 29.7% in EGFR HER2 with （ P 〉 0.05） in varied TNM , stage and lymph metastasis. The amplification of HER2 in adenoma was higher than that in squamous lung cancer. The expression of c -jun,c -fos,P21 ,p16 ,p53 in varied TNM were sig- nificant changes （P 〈 0.05 ） but not pathology, p53 was higher in lymph metastasis. The expression of EGFR, HEtL2 ,c -jun,e -fos ,p21 were positive with NSCLC. Conclusion The combined detection of EGFR,HER2 ,e - jun,c -fos,P21 ,p16 ,p53 should helpful for early diagnosis and supply new method of individualized chemotherapy in NSCLC.